Voysey M, et al. - Researchers aimed at determining the sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV). Findings revealed that Typbar TCV substantially reduced the number of serologically defined (sub)clinical infections in infants, children and adults. The recent World Health Organisation recommendations for deployment of typhoid conjugate vaccines in high burden areas had thus been supported.